Unknown PHASE2 INTERVENTIONAL 2-arm NCT01037049

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks?

Sponsor: Royal Marsden NHS Foundation Trust

Conditions Adenocarcinoma Adenocarcinoma of the Rectum Adenocarcinoma, Mucinous Carcinoma Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Cystic, Mucinous, and Serous Neoplasms, Glandular and Epithelial Rectal Diseases

Interventions Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy

Updated 9 times since 2017 Last updated: Sep 14, 2018 Started: Oct 16, 2009 Primary completion: Dec 8, 2014 Completion: Dec 8, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adenocarcinoma and Adenocarcinoma of the Rectum and is currently ongoing. Royal Marsden NHS Foundation Trust leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE2
Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2

▶ Show 4 earlier versions

Oct 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Active Not Recruiting → Unknown Status
Oct 2018 — Oct 2020 [monthly]

Active Not Recruiting PHASE2
Jun 2018 — Oct 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Royal Marsden NHS Foundation Trust

Data source: Royal Marsden NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bath, United Kingdom , Birmingham, United Kingdom , Carshalton, United Kingdom , Chichester, United Kingdom , Colchester, United Kingdom , Croydon, United Kingdom , Dorchester, United Kingdom , Durham, United Kingdom , Gillingham, United Kingdom , Great Yarmouth, United Kingdom and 12 more locations